Abliva AB operates as a biopharmaceutical company, which engages in the research and development of medicines for the treatment of primary mitochondrial diseases. Its projects include KL1333 and NV354. The company was founded by Eskil Elmer on February 1, 2000 and is headquartered in Lund, Sweden.